Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
401
Recruiting Now
401
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT07266428 Phase 1, Phase 2
Recruiting
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advan...
Condition
Advanced Solid Tumors
Enrollment
170 pts
Location
United States, Australia, Brazil
Sponsor
Ottimo Pharma Limited
NCT07227207 Phase 1, Phase 2
Recruiting
A Study of TSRA-196 in Adults With PiZZ Alpha-1 Antitrypsin Deficiency (AATD)
Condition
Alpha-1 Antitrypsin Deficiency (AATD)
Enrollment
72 pts
Location
United States, Australia, Netherlands
Sponsor
Tessera Therapeutics, Inc.
NCT05329532 Phase 1, Phase 2
Recruiting
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer
Condition
Triple Negative Breast Cancer
Enrollment
168 pts
Location
United Kingdom
Sponsor
Scancell Ltd
NCT03457493 Phase 1, Phase 2
Recruiting
The University of Alabama at Birmingham (UAB) Neuroinflammation in Parkinson's D...
Condition
Parkinson Disease
Enrollment
205 pts
Location
United States
Sponsor
University of Alabama at Birmi
NCT07143448 Phase 1, Phase 2
Recruiting
A Study of HS235 for Treatment of Pulmonary Arterial Hypertension (PAH) in Adult...
Condition
Pulmonary Arterial Hypertension
Enrollment
90 pts
Location
United States, Spain, United Kingdom
Sponsor
35Pharma Inc., a GSK company
NCT07642635 Phase 1, Phase 2
Recruiting
Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individ...
Condition
Duchenne Muscular Dystrophy (DMD)
Enrollment
30 pts
Location
United States
Sponsor
Vanderbilt University Medical
NCT06802835 Phase 1, Phase 2
Recruiting
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngea...
Condition
Nasopharyngeal Cancinoma (NPC)
Enrollment
148 pts
Location
China
Sponsor
Sun Yat-sen University
NCT03564340 Phase 1, Phase 2
Recruiting
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemipli...
Condition
Recurrent Ovarian Cancer
Enrollment
890 pts
Location
United States, Australia, Belgium
Sponsor
Regeneron Pharmaceuticals
NCT06184035 Phase 1, Phase 2
Recruiting
A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Ad...
Condition
Solid Tumor
Enrollment
90 pts
Location
Australia
Sponsor
Spago Nanomedical AB
NCT07302347 Phase 1, Phase 2
Recruiting
A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or...
Condition
Malignant Neoplasm
Enrollment
20 pts
Location
Japan
Sponsor
Merck Sharp & Dohme LLC
NCT07367815 Phase 1, Phase 2
Recruiting
Allogeneic Adipose Tissue Derived-stem Cells in Alzheimer Disease
Condition
Alzheimer Disease
Enrollment
9 pts
Location
France
Sponsor
University Hospital, Toulouse
NCT07724535 Phase 1, Phase 2
Recruiting
18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
Condition
Cancer
Enrollment
30 pts
Location
China
Sponsor
Peking University Cancer Hospi
NCT07439848 Phase 1, Phase 2
Recruiting
Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as A...
Condition
Acute Respiratory Distress Syndrome
Enrollment
15 pts
Location
Indonesia
Sponsor
PT. Prodia Stem Cell Indonesia
NCT05642455 Phase 1, Phase 2
Recruiting
SPEARHEAD-3 Pediatric Study
Condition
Synovial Sarcoma
Enrollment
20 pts
Location
United States
Sponsor
USWM CT, LLC
NCT05688488 Phase 1, Phase 2
Recruiting
Clinical Study of Curcumin in Preventing Postoperative Adhesion of Bilateral Voc...
Condition
Glottic Web of Larynx
Enrollment
100 pts
Location
China
Sponsor
Eye & ENT Hospital of Fudan Un
NCT06568094 Phase 1, Phase 2
Recruiting
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Adv...
Condition
Prostate Cancer
Enrollment
100 pts
Location
China
Sponsor
Jiangsu HengRui Medicine Co.,
NCT06594679 Phase 1, Phase 2
Recruiting
A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of ...
Condition
Ovarian Cancer
Enrollment
73 pts
Location
Italy
Sponsor
Fondazione IRCCS Istituto Nazi
NCT06237179 Phase 1, Phase 2
Recruiting
Behavioral Exercise Training to Reduce Cardiovascular Disease Risk
Condition
Prostate Cancer
Enrollment
60 pts
Location
United States
Sponsor
Virginia Commonwealth Universi
NCT05143996 Phase 1, Phase 2
Recruiting
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Mye...
Condition
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Enrollment
275 pts
Location
United States
Sponsor
Cullinan Therapeutics Inc.
NCT03315546 Phase 1, Phase 2
Recruiting
Radiotherapy Delivery in Deep Inspiration for Pediatric Patients
Condition
Pediatric Cancer
Enrollment
25 pts
Location
Denmark, Finland
Sponsor
Copenhagen University Hospital
NCT06997796 Phase 1, Phase 2
Recruiting
Treatment of Nosebleeds in the Emergency Department With Powder Tranexamic Acid
Condition
Epistaxis Nosebleed
Enrollment
24 pts
Location
Canada
Sponsor
Dr. Anne Conlin
NCT04818203 Phase 1, Phase 2
Recruiting
A Study on the Anti-Wrinkle Efficacy Assessment and Safety Evaluation of the Clu...
Condition
Crow's Feet
Enrollment
80 pts
Location
South Korea
Sponsor
S.Biomedics Co., Ltd.
NCT06930703 Phase 1, Phase 2
Recruiting
Cannabidiol in Sickle Cell Disease
Condition
Sickle Cell Disease
Enrollment
52 pts
Location
United States
Sponsor
Icahn School of Medicine at Mo
NCT06085729 Phase 1, Phase 2
Recruiting
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin an...
Condition
Prostate Cancer
Enrollment
30 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT05978102 Phase 1, Phase 2
Recruiting
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With...
Condition
Advanced Solid Tumor
Enrollment
183 pts
Location
China
Sponsor
The Fourth Affiliated Hospital
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology